JP2010116404A5 - - Google Patents

Download PDF

Info

Publication number
JP2010116404A5
JP2010116404A5 JP2010007505A JP2010007505A JP2010116404A5 JP 2010116404 A5 JP2010116404 A5 JP 2010116404A5 JP 2010007505 A JP2010007505 A JP 2010007505A JP 2010007505 A JP2010007505 A JP 2010007505A JP 2010116404 A5 JP2010116404 A5 JP 2010116404A5
Authority
JP
Japan
Prior art keywords
composition
anabaseine
methoxy
hydrogen
phenyl ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010007505A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010116404A (ja
Filing date
Publication date
Priority claimed from US08/924,008 external-priority patent/US5977144A/en
Application filed filed Critical
Publication of JP2010116404A publication Critical patent/JP2010116404A/ja
Publication of JP2010116404A5 publication Critical patent/JP2010116404A5/ja
Withdrawn legal-status Critical Current

Links

JP2010007505A 1997-08-29 2010-01-15 神経細胞ニコチン性α７レセプタアゴニストとしてのベンジリデン−およびシンナミリデン−アナバセイン Withdrawn JP2010116404A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/924,008 US5977144A (en) 1992-08-31 1997-08-29 Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000507667A Division JP4511023B2 (ja) 1997-08-29 1998-08-28 神経細胞ニコチン性α７レセプタアゴニストとしてのベンジリデン−およびシンナミリデン−アナバセイン

Publications (2)

Publication Number Publication Date
JP2010116404A JP2010116404A (ja) 2010-05-27
JP2010116404A5 true JP2010116404A5 (enExample) 2011-05-12

Family

ID=25449581

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000507667A Expired - Fee Related JP4511023B2 (ja) 1997-08-29 1998-08-28 神経細胞ニコチン性α７レセプタアゴニストとしてのベンジリデン−およびシンナミリデン−アナバセイン
JP2010007505A Withdrawn JP2010116404A (ja) 1997-08-29 2010-01-15 神経細胞ニコチン性α７レセプタアゴニストとしてのベンジリデン−およびシンナミリデン−アナバセイン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000507667A Expired - Fee Related JP4511023B2 (ja) 1997-08-29 1998-08-28 神経細胞ニコチン性α７レセプタアゴニストとしてのベンジリデン−およびシンナミリデン−アナバセイン

Country Status (5)

Country Link
US (1) US5977144A (enExample)
EP (1) EP1045842B1 (enExample)
JP (2) JP4511023B2 (enExample)
DE (1) DE69814688T2 (enExample)
WO (1) WO1999010338A2 (enExample)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001008684A1 (en) * 1999-07-28 2001-02-08 The Board Of Trustees Of The Leland Stanford Junior University Nicotine in therapeutic angiogenesis and vasculogenesis
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
EP1381603A2 (en) 2000-08-18 2004-01-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
US6500840B2 (en) 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001284646A1 (en) 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US20050130990A1 (en) * 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
CA2341952A1 (en) * 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
WO2003018585A1 (en) 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
BR0212123A (pt) * 2001-08-24 2004-07-20 Upjohn Co 7-aza[2.2.1]biciclo-heptanos substituìdos com arila para o tratamento de doenças
EP1425286B1 (en) * 2001-09-12 2007-02-28 Pharmacia & Upjohn Company LLC Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases
EP1432707B1 (en) 2001-10-02 2012-03-28 Pharmacia & Upjohn Company LLC Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
MXPA04004464A (es) * 2001-11-08 2004-08-11 Upjohn Co Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
US6951868B2 (en) 2001-11-09 2005-10-04 Pfizer Inc. Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease
AU2002360598B2 (en) * 2001-12-14 2008-02-14 Medical College Of Georgia Research Institute, Inc. Methods and compositions for treatment of central nervous system disorders
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US6852741B2 (en) 2001-12-31 2005-02-08 University Of Florida Compositions and methods for treatment of neurological disorders
JP2005522456A (ja) 2002-02-15 2005-07-28 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Ｃｎｓ関連障害治療のためのアザビシクロ置換ベンゾイルアミドおよびチオアミド
BR0307782A (pt) * 2002-02-19 2005-01-04 Upjohn Co Compostos azabiciclo para o tratamento de doença
US6858613B2 (en) * 2002-02-19 2005-02-22 Pfizer Inc. Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
WO2003072578A1 (en) * 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8039459B2 (en) * 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US7176198B2 (en) * 2002-08-01 2007-02-13 Pfizer Inc. 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease
WO2004019943A1 (en) * 2002-08-30 2004-03-11 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegenerative diseases
CA2503786A1 (en) * 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Compounds having both alpha7 nicotinic agonist activity and 5ht, antagonist activity for treatment of cns diseases
DE10251963A1 (de) 2002-11-08 2004-05-19 Lts Lohmann Therapie-Systeme Ag Transmucosale pharmazeutische Darreichungsform
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
ES2462545T3 (es) * 2002-12-06 2014-05-23 The Feinstein Institute For Medical Research Un procedimiento para la determinación de un agonista colinérgico selectivo para un receptor alfa7 nicotínico
US7087106B2 (en) * 2003-02-20 2006-08-08 University Of Florida Materials and methods for inhibiting fouling of surfaces exposed to aquatic environments
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
EP1734941A2 (en) 2004-03-25 2006-12-27 The Feinstein Institute for Medical Research Neural tourniquet
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US20050288333A1 (en) * 2004-06-08 2005-12-29 Kem William R Controlling angiogenesis with anabaseine analogs
WO2006073484A2 (en) 2004-12-27 2006-07-13 North Shore-Long Island Jewish Research Institute Treating inflammatory disorders by electrical vagus nerve stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
CA2610795C (en) * 2005-06-07 2015-01-06 University Of Florida Research Foundation, Inc. 3-arylidene-anabaseine compounds as alpha 7 nicotitnic receptor selective ligands
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
US7662965B2 (en) 2006-01-26 2010-02-16 Cornerstone Therapeutics, Inc. Anabaseine derivatives, pharmaceutical compositions and method of use thereof
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) * 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
CN101952276B (zh) * 2007-12-07 2014-10-22 Abbvie德国有限责任两合公司 5-卤素取代的羟吲哚衍生物和其用于治疗加压素依赖性疾病的用途
EP2231643B1 (de) 2007-12-07 2012-10-31 Abbott GmbH & Co. KG Amidomethyl-substitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
CN102026995B (zh) 2007-12-07 2014-10-29 Abbvie德国有限责任两合公司 5，6-二取代的羟吲哚衍生物和其用途
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
EP2271344A4 (en) 2008-03-31 2011-04-27 Univ South Florida METHOD FOR TREATING ILLNESS-RELATED ATAXIA AND NON-ATTACHIC IMBALANCE
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
CN102215909B (zh) 2008-11-18 2014-09-10 赛博恩特医疗器械公司 优化用于消炎刺激的电极放置的装置和方法
CA2894860C (en) 2008-11-19 2018-11-06 Gerhard Koenig Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
JP5808319B2 (ja) * 2009-05-11 2015-11-10 フォルム ファーマシューティカルズ、インコーポレイテッド アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療
WO2010138600A2 (en) 2009-05-29 2010-12-02 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
EP2440284B1 (en) 2009-06-09 2018-09-12 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
EP2515996B1 (en) 2009-12-23 2019-09-18 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
MX357676B (es) 2010-05-17 2018-07-18 Forum Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin- 3-il)benzo[b]tiofeno-2-carboxamida monohidratado.
WO2012031220A2 (en) 2010-09-03 2012-03-08 University Of Florida Research Foundation, Inc. Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
EP3666272A1 (en) 2012-05-08 2020-06-17 Forum Pharmaceuticals Inc. Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
EP3405255B1 (en) 2016-01-20 2025-12-31 Setpoint Medical Corporation IMPLANTABLE MICROSTIMULATORS AND INDUCTION CHARGING SYSTEMS
CN108882885A (zh) 2016-01-20 2018-11-23 赛博恩特医疗器械公司 迷走神经刺激的控制
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US11096932B2 (en) 2016-09-29 2021-08-24 The Uab Research Foundation Methods and compositions for increasing mucus clearance
EP3668402B1 (en) 2017-08-14 2024-07-31 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US20210255202A1 (en) 2018-06-13 2021-08-19 Michael R. D'Andrea Methods and dosing regimens for preventing or delaying onset of alzheimer's disease and other forms of dementia and mild congnitive impairment
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US12343535B2 (en) 2019-04-12 2025-07-01 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
EP4090424A4 (en) 2020-01-13 2024-02-21 The Feinstein Institutes for Medical Research TREATMENT OF BLEEDING AND BLEEDING DISORDERS BY HIGH-INTENSITY FOCUSED ULTRASONIC STIMULATION OF THE SPLEEN
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
AU2021286756A1 (en) * 2020-06-09 2023-03-23 Elkazaz, Mohamed, Fadly Abd El Ghany A novel medicament for immune modulation and treating chronic or hyper inflammation
WO2022245878A1 (en) 2021-05-17 2022-11-24 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
EP4466064A4 (en) 2022-01-20 2026-01-14 Setpoint Medical Corp TREATMENT OF INFLAMMATORY DISORDERS

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3275625A (en) * 1966-09-27 Derivatives of
US3426130A (en) * 1960-12-19 1969-02-04 Squibb & Sons Inc Compositions containing a benzothiadiazinesulfonamide 1,1-dioxide
US3247213A (en) * 1961-04-12 1966-04-19 Shell Oil Co Heterocyclic nitrogen compounds
US3265573A (en) * 1962-07-27 1966-08-09 Squibb & Sons Inc Benzothiadiazinesulfonamide-1, 1-dioxide composition
US4155909A (en) * 1977-06-13 1979-05-22 Philip Morris Incorporated 2-Alkyl nicotinoids and processes for their production
US4195645A (en) * 1978-03-13 1980-04-01 Celanese Corporation Tobacco-substitute smoking material
US4728605A (en) * 1984-07-31 1988-03-01 Fudenberg Herman H Methods for recognizing and diagnosing subsets of Alzheimer's disease associated with immune system dysfunction, and for the in vitro testing of possible therapeutic agents for treatment of same
US4965074A (en) * 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
US5015570A (en) * 1988-05-13 1991-05-14 Molecular Therapeutics, Inc. Molecular diagnosis of Alzheimer Disease
GB8929331D0 (en) * 1989-12-29 1990-02-28 Shell Int Research Piperidine derivatives
JP2657583B2 (ja) * 1991-03-01 1997-09-24 ユニバーシテイ オブ フロリダ リサーチ ファンデーション インコーポレイテッド 神経系変性疾患の治療に対するニコチン類似体の利用
US5242934A (en) * 1992-03-02 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5212188A (en) * 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
US5242935A (en) * 1992-03-06 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5227385A (en) * 1992-03-13 1993-07-13 Wake Forest University Method for treatment of neurodegenerative diseases
US5187169A (en) * 1992-04-10 1993-02-16 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5276043A (en) * 1992-04-10 1994-01-04 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5227391A (en) * 1992-04-10 1993-07-13 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5214060A (en) * 1992-04-10 1993-05-25 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5232932A (en) * 1992-05-21 1993-08-03 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5232933A (en) * 1992-05-21 1993-08-03 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5242916A (en) * 1992-07-07 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5248690A (en) * 1992-07-07 1993-09-28 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
AU674541B2 (en) * 1992-08-31 1997-01-02 University Of Florida Research Foundation, Inc. Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
US5595972A (en) * 1993-06-29 1997-01-21 University Of Utah Research Foundation Conotoxin peptides
US5488049A (en) * 1993-12-10 1996-01-30 Fidia - Georgetown Institute For The Neuro-Sciences Method of treating learning and memory disorders using benzothiadiazide derivatives as nootropic agents
PT777671E (pt) * 1994-08-24 2000-08-31 Astrazeneca Ab Compostos espiro-azabiciclicos uteis em terapia
US5703100A (en) * 1994-11-10 1997-12-30 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US6177242B1 (en) * 1994-12-14 2001-01-23 Institut Pasteur Genomic DNA fragments containing regulatory and coding sequences for the β2-subunit of the neuronal nicotinic acetylcholine receptor and transgenic animals made using these fragments or mutated fragments
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy

Similar Documents

Publication Publication Date Title
JP2011037901A5 (enExample)
JP2020500862A5 (enExample)
JP2007508361A5 (enExample)
JP2014505107A5 (enExample)
RU2007111711A (ru) Производные трициклического лактама в качестве ингибиторов 11-бэта-гидроксистероидной дегидрогеназы
JP2012533546A5 (enExample)
JP2010155827A5 (enExample)
JP2008501000A5 (enExample)
JP2006143751A5 (enExample)
JP2013510120A5 (enExample)
JP2011527332A5 (enExample)
JP2016040288A5 (enExample)
TN2012000139A1 (en) Cgrp receptor antagonists
JP2014508811A5 (enExample)
JP2013542261A5 (enExample)
JP2009529541A5 (enExample)
JP2015517579A5 (enExample)
EA022815B1 (ru) Антагонист рецептора cgrp
JP2009523760A5 (enExample)
JP2014507455A5 (enExample)
JP2013521286A5 (enExample)
JP2015501799A5 (enExample)
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
JP2012532883A5 (enExample)
JP2014503593A5 (enExample)